26 July 2020 in American Journal of Transplantation
We describe a patient with liver metastases from colorectal cancer treated with chemotherapy and hepatic resection, who developed unresectable multifocal liver recurrence and who received liver transplantation using a novel planned technique: heterotopic transplantation of segment 2‐3 in the splenic fossa with splenectomy and delayed hepatectomy after regeneration of the transplanted graft. We transplanted a segmental liver graft after in‐situ splitting without any impact on the waiting list, as it was previously rejected for pediatric and adult transplantation. The volume of the graft was insufficient to provide liver function to the recipient, so we performed this novel operation. The graft was anastomosed to the splenic vessels after splenectomy, and the native liver portal flow was modulated to enhance graft regeneration, leaving the native recipient liver intact. The volume of the graft doubled during the next two weeks and the native liver was removed. After 8 months, the patient lives with a functioning liver in the splenic fossa and without abdominal tumor recurrence. This is the first case reported of a segmental graft transplanted replacing the spleen and modulating the portal flow to favor graft growth, with delayed native hepatectomy.
28 April 2025 in Clinical Transplantation
Background: The role of machine perfusion after kidney transplantation (KT) in extended criteria donors (ECD) is unclear, and the current evidence in the literature remains controversial.Methods: We present an open‐label single center randomized trial where 109 patients undergoing KT with ECD grafts between January 2019 and December 2022 were randomized to receive kidneys treated with either hypothermic oxygenated perfusion (HOPE, n = 54) or static cold storage (SCS, n = 55) alone. The primary endpoint was the incidence of delayed graft function (DGF). The secondary endpoints included postoperative complications and graft function and survival in the first year after KT.Results: The trial failed to meet its primary endpoint. DGF developed in 31 (57%) and 37 (67%) patients in the HOPE and SCS groups, respectively (p = 0.3). Posthoc analysis showed that HOPE was associated with a lower risk for DGF for grafts from donors aged 60 years or older (OR 0.32, 95% CI 0.12–0.87, p = 0.026) and in patients undergoing dual KTs (OR 0.22, 95% CI 0.06–0.87, p = 0.031).Conclusions: HOPE does not reduce the rate of DGF after KT in ECD donors. However, HOPE appears to be associated with better outcomes in the case of older donors and dual KTs.
28 April 2026 in Artificial Organs
Background: The advent of machine perfusion (MP) has significantly improved post‐liver transplantation (post‐LT) outcomes, potentially enabling the use of increasingly marginal grafts and expanding the organ donor pool. Methods: We present a retrospective cohort study of consecutive adult patients who underwent LT between 2018 and 2023 at a leading Italian institution. The objective was to evaluate outcomes following the use of hypothermic oxygenated perfusion (HOPE) in high‐risk grafts. Results: A total of 507 patients were included in the final analysis, of whom 420 (83%) received extended criteria donor (ECD) grafts. Among ECD grafts, 62 (15%) were from donation after circulatory death (DCD) donors, and 64 (15%) were previously discarded by other centers. HOPE was applied in 248 (49%) cases. Recipients in the HOPE group experienced significantly lower rates of early allograft dysfunction (EAD) (20% vs. 32%, p = 0.007), primary nonfunction (2% vs. 7%, p = 0.017), and severe postoperative complications (Clavien–Dindo grade ≥ 3b) (19% vs. 28%, p = 0.026). Notably, marginal grafts treated with HOPE achieved survival outcomes comparable to those of standard risk. Conclusions: HOPE is associated with improved outcomes in LT using ECD grafts and can enable the safe use of higher‐risk organs with acceptable results when performed in experienced centers.
3 April 2026 in JHEP Reports
Early enthusiasm for adjuvant immunotherapy with atezolizumab plus bevacizumab after curative treatment of hepatocellular carcinoma (HCC) has been tempered by longer follow-up, which questioned the durability of benefit. Beyond treatment efficacy, inadequate patient selection may have contributed. We aimed to externally validate the high-risk criteria adopted in the IMbrave050 trial and to investigate whether integrating liver stiffness measurement (LSM) could improve recurrence risk stratification and provide a pragmatic framework for future adjuvant trial enrolment. We retrospectively analysed 147 patients who underwent curative liver resection for HCC between 2010 and 2020 at our institution. High-risk status was defined by IMbrave050 criteria. LSM was assessed preoperatively. Competing-risk analyses (Fine-Gray) evaluated predictors of recurrence and liver-related outcomes; we quantified the added value of LSM using category-based net reclassification improvement. We then defined an integrated selection rule (Integrated Model for Adjuvant Trial Selection in Hepatocellular Carcinoma [IMAT-HCC]) as IMbrave050-IN or IMbrave050-OUT with LSM ≥15 kPa. Over a median 34 months, 88/147 patients (59.9%) recurred. Both IMbrave050 high-risk features and LSM ≥15 kPa were independently associated with recurrence (subhazard ratio [SHR] 1.66, 95% CI 1.09-2.54; and SHR 1.62, 95% CI 1.07-2.47, respectively). Patients classified as IMbrave050-OUT but with LSM ≥15 kPa showed recurrence rates comparable to IMbrave050-IN patients, whereas those with LSM <15 kPa had substantially lower risk. The IMAT-HCC rule provided clearer separation of cumulative incidence functions than IMbrave050 alone and improved patient reclassification (overall net reclassification improvement 8.0%), driven by correct up-classification of patients who eventually recurred. Integrating LSM into tumour-based risk criteria refines identification of biologically high-risk patients after resection and improves exclusion of truly low-risk individuals. IMAT-HCC represents a simple, non-invasive and trial-ready selection rule that may enhance enrichment strategies for future adjuvant trials in HCC. This study demonstrates that integrating liver stiffness measurement with tumour-based criteria refines the identification of patients at high biological risk of recurrence after curative resection for hepatocellular carcinoma. By addressing the limitations of purely tumour-centric selection strategies (i.e. IMbrave050 criteria), it highlights the prognostic relevance of the underlying liver disease in shaping post-resection outcomes. Incorporation of this approach into clinical research and trial design could improve risk stratification and patient selection for adjuvant therapies, while avoiding overgeneralisation given the retrospective, single-centre nature of the study.